Recently, Professor Ivan O. Rosas,Director of Respiratory, Sleep and Critical Care Medicine at Baylor College of Medicine in the United States, visited Shenzhen Cell Valley for exchange. Professor Rosas toured the Cell Valley's Smart Exhibition Hall and R&D laboratories, and under the guidance of Chairman Professor Shi Yuanyuan, systematically learned about Cell Valley's development history, strategic layout, team building in the field of cell therapy CRO/CDMO, as well as the unique advantages of Cell Valley in core retroviral vector preparation and production. Dr. Ivan highly commended Cell Valley for achieving standardized, normalized, and professional viral vector preparation and production processes.

Subsequently, Professor Rosas engaged in academic exchanges with Chairman Professor Shi Yuanyuan, Chief Scientist Professor Wang Jianxun, and the Cell Valley R&D team. Professor Rosas first provided a detailed introduction to the research teams and fields at Baylor College of Medicine, then delved into his team's advanced technologies and achievements in pulmonary fibrosis disease research, and conducted in-depth discussions with attendees on immune regulation and target discovery in pulmonary fibrosis diseases.

During the meeting discussions, Professor Rosas, Chairman Professor Shi Yuanyuan, and Chief Scientist Professor Wang Jianxun agreed that developing cell-based drugs for pulmonary fibrosis treatment using retroviral vector technology holds broad prospects. Combining Professor Rosas' team's clinical research resources and Cell Valley's technological production advantages, both teams will jointly explore and collaboratively develop cell therapy drugs targeting pulmonary fibrosis diseases, breaking through the current situation of insufficient therapeutic options for pulmonary fibrosis.

Finally, Professor Rosas took a group photo with all the participants.

Ivan O. Rosas: Dr. Ivan Rosas, Professor, Director of Respiratory, Sleep and Critical Care Medicine at Baylor College of Medicine, and Director of the Lung Health Research Division. He previously served as an NIH researcher, and as Assistant Professor, Associate Professor, and  Professor of Respiratory and Critical Care Medicine at Brigham and Women's Hospital (BWH), affiliated with Harvard University. He has published numerous papers as corresponding author in top journals such as the New England Journal of Medicine (N Eng J Med), American Journal of Respiratory and Critical Care Medicine (AJRCCM), and Sciences Advances.

Dr. Rosas' primary research interests lie in the prevention, diagnosis, and treatment of pulmonary fibrosis, a disease affecting genetically susceptible populations and the elderly. Clinically, Dr. Rosas' program focuses on identifying populations at risk for developing pulmonary fibrosis, identifying disease biomarkers, and designing and executing clinical trials testing new therapies for pulmonary fibrosis. In the laboratory, his research team employs cutting-edge genomic technologies and translational models to determine how specific molecular disturbances contribute to the development and progression of parenchymal lung diseases. The long-term goal of this translational research program is to better understand the mechanisms driving disease progression and to inform the development of new diagnostic and therapeutic strategies for patients with fibrotic lung diseases.

Baylor College of Medicine is a private medical school in the United States, considered one of the most distinguished medical schools globally. The medical school has been a leader in the field of biomedical research worldwide for over 100 years since its founding in 1900. In the USNEWS rankings of medical schools nationwide, Baylor College of Medicine's medical research program ranks in the top ten nationally, and its clinical care ranks in the top eleven.